A Mendelian randomization study: Genetically predicted dopamine 4-sulfate to dopamine 3-O-sulfate ratio mediates the association between chemokine C-C motif ligand 11 and polycystic ovary syndrome

孟德尔随机化研究:基因预测的多巴胺4-硫酸酯与多巴胺3-O-硫酸酯比值介导趋化因子CC基序配体11与多囊卵巢综合征之间的关联

阅读:1

Abstract

This Mendelian randomization (MR) study aims to elucidate the causal pathways between circulating chemokine C-C motif ligand 11 (CCL11) levels and the pathogenesis of polycystic ovary syndrome (PCOS), with a specific focus on the mediating role of dopamine sulfate isomers. Using genome-wide association data from 14,824 European participants (for CCL11 quantitative trait loci) and 2,01,005 individuals (including 1424 PCOS cases), we performed 2-sample MR analyses, with inverse-variance weighting as the primary estimator. Sensitivity analyses included MR-Egger regression and weighted median approaches. Genetic predisposition to elevated CCL11 concentrations was significantly associated with an increased risk of PCOS (odds ratio = 1.28 per standard deviation increase, 95% confidence interval [CI]: 1.04-1.58, P = .021). Reverse causality analysis showed no significant association (odds ratio = 0.98, 95% CI: 0.95-1.01). Two-step mediation MR revealed that 8.8% (95% CI: 2.1-15.5%) of CCL11's effect on PCOS is mediated through altered dopamine 4-sulfate/3-O-sulfate ratios, indicating partial neuroendocrine mediation. Our findings identify CCL11 as an etiological factor in PCOS development, with dopamine metabolite imbalance representing a novel intermediary pathway. The predominant mechanisms underlying this association require further characterization, necessitating exploration of additional inflammatory and metabolic mediators. These results enhance understanding of chemokine-neuroendocrine interactions in PCOS pathophysiology and highlight potential therapeutic targets.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。